Specific antibodies against vaccine-preventable infections: A mother-infant cohort study

BMJ Open

Volumn 3, Issue 4, 2013, Pages

  Jones, Christine ^a,b   Pollock, Louisa ^a   Barnett, Sara M ^a   Battersby, Anna ^a   Kampmann, Beate ^a,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c Vaccinology Theme   (Gambia)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G; MATERNAL ANTIBODY; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; TETANUS TOXOID;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAEMOPHILUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFECTION PREVENTION; MALE; MOTHER CHILD RELATION; PERTUSSIS; PLACENTAL TRANSFER; PNEUMOCOCCAL INFECTION; PROSPECTIVE STUDY; TETANUS;

EID: 84877710649     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-002473     Document Type: Article

References (52)

1. Health Protection Agency. Press release: cases of whooping cough decline after record numbers in 2012. 2013. http://www.hpa.org.uk/NewsCentre/ NationalPressReleases/2013PressReleases/ 130201Casesofwhoopingcoughdeclineafterrecordnumbers/(accessed 4 Mar 2013).
2. Joint Committee on Vaccination and Immunisation. Minutes of Teleconference on Pertussis 30th August 2012. 2012. https://www.wp.dh.gov.uk/ transparency/files/2012/09/
3. Pertussis-teleconference-minute-to-committee-v4.pdf (accessed 4 Mar 2013).
4. Blencowe H, Lawn J, Vandelaer J, et al. Tetanus toxoid immunization to reduce mortality from neonatal tetanus. Int J Epidemiol 2010;39(Suppl 1):i102-9.
5. Cherry JD, Gornbein J, Heininger U, et al. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998;16:1901-6. (Pubitemid 28473933)
6. Storsaeter J, Hallander HO, Gustafsson L, et al. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998;16:1907-16. (Pubitemid 28473934)
7. Taranger J, Trollfors B, Lagergard T, et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis 2000;181:1010-13. (Pubitemid 30194485)
8. Storsaeter J, Hallander HO, Gustafsson L, et al. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine 2003;21:3542-9. (Pubitemid 37338177)
9. Gall SA, Myers J, Pichichero M. Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstetr Gynecol 2011;204:334 e1-5.
10. World Health Organization. Tetanus vaccine. Wkly Epidemiol Rec 2006;81:198-208.
11. Kayhty H, Peltola H, Karanko V, et al. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983;147:1100. (Pubitemid 13068358)
12. Agbarakwe AE, Griffiths H, Begg N, et al. Avidity of specific IgG antibodies elicited by immunisation against Haemophilus influenzae type b. J Clin Pathol 1995;48:206-9.
13. Schauer U, Stemberg F, Rieger CH, et al. Levels of antibodies specific to tetanus toxoid, Haemophilus influenzae type b, and pneumococcal capsular polysaccharide in healthy children and adults. Clin Diagnostic Lab Immunol 2003;10:202-7. (Pubitemid 36314441)
14. Healy CM, Munoz FM, Rench MA, et al. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis 2004;190:335-40. (Pubitemid 38951975)
15. Healy CM, Rench MA, Edwards KM, et al. Pertussis serostatus among neonates born to Hispanic women. Clin Infect Dis 2006;42:1439-42.
16. Belloni C, De Silvestri A, Tinelli C, et al. Immunogenicity of a three-component acellular pertussis vaccine administered at birth. Pediatrics 2003;111(5 Pt 1):1042-5. (Pubitemid 36542619)
17. de Voer RM, van der Klis FR, Nooitgedagt JE, et al. Seroprevalence and placental transportation of maternal antibodies specific for Neisseria meningitidis serogroup C, Haemophilus influenzae type B, diphtheria, tetanus, and pertussis. Clin Infect Dis 2009;49:58-64.
18. van den Berg JP, Westerbeek EA, Berbers GA, et al. Transplacental transport of IgG antibodies specific for pertussis, diphtheria, tetanus, haemophilus influenzae type b, and Neisseria meningitidis serogroup C is lower in preterm compared with term infants. Pediatr Infect Dis J 2010;29:801-5.
19. Jones CE, Naidoo S, De Beer C, et al. Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants. JAMA 2011;305:576-84.
20. Shakib JH, Ralston S, Raissy HH, et al. Pertussis antibodies in postpartum women and their newborns. J Perinatol 2010;30:93-7.
21. Palmeira P, Quinello C, Silveira-Lessa AL, et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012;2012:985646.
22. Scott S, Cumberland P, Shulman CE, et al. Neonatal measles immunity in rural Kenya: the influence of HIV and placental malaria infections on placental transfer of antibodies and levels of antibody in maternal and cord serum samples. J Infect Dis 2005;191:1854-60. (Pubitemid 40705392)
23. Cumberland P, Shulman CE, Maple PA, et al. Maternal HIV infection and placental malaria reduce transplacental antibody transfer and tetanus antibody levels in newborns in Kenya. J Infect Dis 2007;196:550-7. (Pubitemid 47206101)
24. de Moraes-Pinto MI, Farhat CK, Carbonare SB, et al. Maternally acquired immunity in newborns from women infected by the human immunodeficiency virus. Acta Paediatr 1993;82:1034-8. (Pubitemid 24051393)
25. de Moraes-Pinto MI, Almeida AC, Kenj G, et al. Placental transfer and maternally acquired neonatal IgG immunity in human immunodeficiency virus infection. J Infect Dis 1996;173:1077-84. (Pubitemid 26251448)
26. Wendelboe AM, Van Rie A, Salmaso S, et al. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005;24(5 Suppl):S58-61. (Pubitemid 40676539)
27. Cattaneo LA, Reed GW, Haase DH, et al. The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1-65 years. J Infect Dis 1996;173:1256-9. (Pubitemid 26251472)
28. Office for National Statistics. Live births in England and Wales by characteristics of Mother 1, 2010, 2011.http://www.ons.gov.uk/ons/dcp171778- 239220.pdf (accessed 4 Mar 2013).
29. National Records of Scotland. Statistics for vital events (Birth time series data), 2011. http://www.gro-scotland.gov.uk/statistics/theme/vital- events/births/time-series.html (accessed 4 Mar 2013).
30. Van Savage J, Decker MD, Edwards KM, et al. Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis 1990;161:487-92. (Pubitemid 20107950)
31. Leino T, Auranen K, Makela PH, et al. Dynamics of natural immunity caused by subclinical infections, case study on Haemophilus influenzae type b (Hib). Epidemiol Infect 2000;125:583-91. (Pubitemid 32156848)
32. Ladhani SN, Ramsay M, Slack MP. The impact of Haemophilus influenzae serotype B resurgence on the epidemiology of childhood invasive Haemophilus influenzae disease in England and Wales. Pediatr Infect Dis J 2011;30:893-5.
33. Ladhani S, Neely F, Heath PT, et al. Recommendations for the prevention of secondary Haemophilus influenzae type b (Hib) disease. J Infect 2009;58:3-14.
34. Roper MH, Vandelaer JH, Gasse FL. Maternal and neonatal tetanus. Lancet 2007;370:1947-59. (Pubitemid 350192632)
35. Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011;11:760-8.
36. Flasche S, Van Hoek AJ, Sheasby E, et al. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med 2011;8: e1001017.
37. Health Protection Agency. Cumulative weekly number of reports of invasive pneumococcal disease due to any of the serotypes not in Prevenar 13: Children aged <2 years in England and Wales. 2012. http://www.hpa.org.uk/Topics/ InfectiousDiseases/InfectionsAZ/Pneumococcal/EpidemiologicalDataPneumococcal/ CurrentEpidemiologyPneumococcal/NotInPrevenar13/ pneumo04CummulativeweeklyUnder2NOTINPrevenar13Vacc/(accessed 4 Mar 2013).
38. McNally LM, Jeena PM, Gajee K, et al. Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: a prospective descriptive study. Lancet 2007;369:1440-51. (Pubitemid 46635781)
39. Shahid NS, Steinhoff MC, Hoque SS, et al. Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine. Lancet 1995;346:1252-7.
40. Munoz FM, Englund JA, Cheesman CC, et al. Maternal immunization with pneumococcal polysaccharide vaccine in the third trimester of gestation. Vaccine 2001;20:826-37. (Pubitemid 34015822)
41. Lehmann D, Pomat WS, Riley ID, et al. Studies of maternal immunisation with pneumococcal polysaccharide vaccine in Papua New Guinea. Vaccine 2003;21:3446-50. (Pubitemid 36792101)
42. Holmlund E, Nohynek H, Quiambao B, et al. Mother-infant vaccination with pneumococcal polysaccharide vaccine: persistence of maternal antibodies and responses of infants to vaccination. Vaccine 2011;29:4565-75.
43. Quiambao BP, Nohynek HM, Kayhty H, et al. Immunogenicity and reactogenicity of 23-valent pneumococcal polysaccharide vaccine among pregnant Filipino women and placental transfer of antibodies. Vaccine 2007;25:4470-7. (Pubitemid 46705421)
44. Chaithongwongwatthana S, Yamasmit W, Limpongsanurak S, et al. Pneumococcal vaccination during pregnancy for preventing infant infection. Cochrane Database Syst Rev 2012;7: CD004903.
45. Riffelmann M, Thiel K, Schmetz J, et al. Performance of commercial enzyme-linked immunosorbent assays for detection of antibodies to Bordetella pertussis. J Clin Microbiol 2010;48:4459-63.
46. Guiso N, Berbers G, Fry NK, et al. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. Eur J Clin Microbiol Infect Dis 2011;30:307-12.
47. Kosters K, Riffelmann M, Dohrn B, et al. Comparison of five commercial enzyme-linked immunosorbent assays for detection of antibodies to Bordetella pertussis. Clin Diagnostic Lab Immunol 2000;7:422-6. (Pubitemid 30263035)
48. Lindsey B, Jones C, Kampmann B. Bridging the gap: maternal immunisation as a means to reduce neonatal deaths from infectious diseases. Pathog Glob Health 2012;106:137-8.
49. Esposito S, Bosis S, Morlacchi L, et al. Can infants be protected by means of maternal vaccination? Clin Microbiol Infect 2012;18(Suppl 5):85-92.
50. Englund JA, Anderson EL, Reed GF, et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics 1995;96(3 Pt 2):580-4.
51. Department of Health. Pertussis Vaccine Uptake in Pregnant Women November 2012. 2013. http://immunisation.dh.gov.uk/pert-vac-uptake-preg-nov-12/(accessed 20 Feb 2013).
52. Department of Health. Seasonal influenzae vaccine uptake amongst GP patient groups in England. Winter season 2011/12. 2012. https://www.wp.dh.gov. uk/immunisation/files/2012/06/Flu-vaccine-uptake-GP-patients-2011.12.pdf (accessed 20 Feb 2013).